Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell more than 8% in the afternoon. Revenue in the first half of the year only increased slightly year-on-year, and price increases contributed to the main profit

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) fell by more than 8% in the afternoon. As of press release, it was down 4.22% to HK$26.32, with a turnover of HK$1,613 billion.

According to the news, Zhaoyan Pharmaceutical expects revenue of about 669 million yuan to 739 million yuan in the first half of the year, an increase of about 0% to 10.5% over the previous year; net profit to the mother of 600 million yuan to 900 million yuan, an increase of 884.9% to 1377.4% over the previous year. The performance explosion was not due to a sharp improvement in order profits from the main security assessment business, but from the appreciation of the company's experimental monkey assets.

According to the announcement, changes in the fair value of biological assets such as experimental monkeys contributed 703 million yuan to 777 million yuan in net profit during the period. According to a report by the Science and Technology Innovation Board Daily, the overall price of experimental monkeys on the market is currently rising. The price of a single crab-eating monkey between the ages of 3-5 is generally in the range of 150,000 to 200,000, while the price of a single rhesus monkey is around 120,000 yuan; the order schedule for the Zhaoyan New Drug Experimental Monkey is quite tight at this stage. Currently, it is around 4-5 months.